

Exploring the effect of disturbance in insulin metabolism on the treatment response of hepatitis C virus to find options to improve response rate

Submission date 07/12/2009	Recruitment status Stopped	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 15/01/2010	Overall study status Stopped	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 03/09/2014	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Mark Thursz

Contact details

Hepatology Section
Imperial College
St Mary's Campus
Norfolk place
London
United Kingdom
W2 1NY
+44 (0)207 886 1903
m.thursz@imperial.ac.uk

Additional identifiers

EudraCT/CTIS number

2009-016678-34

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

EudraCT No: 2009-016678-34

Study information

Scientific Title

Exploring the relationship between insulin resistance and interferon resistance: options to overcome Hepatitis C Virus (HCV) non-response to pegylated interferon

Study objectives

Hepatitis C virus (HCV) infection is a serious problem. Currently, pegylated interferon and ribavirin treatment can result in cure. However, the average overall cure rate is about 55% of patients. This average depends on the viral genotypes (substrains). For example, the cure rate is lower in HCV genotype 1 and 4 than HCV genotype 2 and 3. In addition, patients with liver cirrhosis (scarring) have a lower chance to respond to treatment. Furthermore, there is new scientific evidence that disturbance in insulin metabolism, which is called insulin resistance, may lower the treatment response. Insulin resistance can be caused by obesity and/or diabetes mellitus (DM). Now, there is new evidence that HCV per se can cause insulin resistance. This means that any patient with HCV infection could have insulin resistance even if he/she is non-obese and non-diabetic. As insulin resistance can decrease the chance of cure in response to current treatment, so improving insulin resistance may improve the treatment response and overall cure rate. Insulin resistance can be improved by pioglitazone oral tablets treatment which is currently used for patients with DM.

The objective of this study is to improve the overall cure rate in response to treatment by pegylated interferon and ribavirin by addition of pioglitazone to improve insulin resistance.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethical approval is in progress. Within December 2010, will apply to:

1. Medicines and Healthcare products Regulatory Agency (MHRA)
2. NHS/Health and Social Care (HSC) R&D office
3. Social Care Research Ethics Committee
4. NHS Ssci

Study design

Prospective open-label study

Primary study design

Interventional

Secondary study design

Other

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet**Health condition(s) or problem(s) studied**

Hepatitis C Virus (HCV) infection

Interventions

In stage 1, we will investigate the physiologic response to pioglitazone therapy by comparing measured total insulin resistance, hepatic insulin resistance, interferon sensitivity and virologic response before and after a 12-week course of pioglitazone.

The total duration of follow-up for stage I will be 13 weeks.

In stage 2, pioglitazone 30 mg will be added to standard therapy for two groups of patients: a) group I consisted of naïve patients with HCV genotype 1 infection and b) group II consisted of patients with hepatitis C and compensated liver cirrhosis (Ishak fibrosis score ≥ 5) who failed to respond to previous treatment. The impact of adding pioglitazone to standard treatment on sustained virologic response (SVR) will be determined after a full course of pegylated interferon and ribavirin treatment in addition to pioglitazone therapy.

The total duration of follow-up for stage II will be 1.5 years.

Updated 03/09/2014: the trial was stopped in 2011 due to poor recruitment.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Insulin resistance:

Total body insulin resistance and hepatic insulin resistance will be measured using the hyperinsulinaemic euglycaemic clamp.

Secondary outcome measures

1. Interferon sensitivity (Interferon-Inducible Protein [IP10] in blood measured by ELISA and in peripheral blood mononuclear cells [PBMC] by mRNA)
2. Viral dynamic response measured by serial HCV PCR levels
3. Treatment response measured by serial HCV PCR levels

Overall study start date

01/02/2010

Completion date

31/01/2012

Reason abandoned (if study stopped)

Participant recruitment issue

Eligibility

Key inclusion criteria

1. Chronic HCV genotype 1 infection
2. Chronic HCV and compensated liver cirrhosis who failed to respond to previous treatment
3. Age >17, <70
4. Eligible for interferon therapy

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

22 patients

Key exclusion criteria

1. HIV or HBV co-infection
2. Current use antidiabetic medication (e.g., insulin, metformin or thiazolidinedione)
3. Significant respiratory, cardiac or renal dysfunction
4. Body Mass Index > 30 kg/m²

Date of first enrolment

01/02/2010

Date of final enrolment

31/01/2012

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Hepatology Section

London

United Kingdom

W2 1NY

Sponsor information

Organisation

Imperial College London and Imperial College Healthcare NHS Trust (UK)

Sponsor details

Joint Research Office
G02, Sir Alexander Fleming Building
South Kensington Campus
London
England
United Kingdom
SW7 2AZ
+44(0)20 7594 1554
lucy.parker@imperial.ac.uk

Sponsor type

University/education

Website

<http://www3.imperial.ac.uk/>

ROR

<https://ror.org/041kmwe10>

Funder(s)**Funder type**

University/education

Funder Name

Imperial College London (UK) - Hepatology Section

Results and Publications**Publication and dissemination plan**

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration